Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Pipeline Landscape and Therapeutics Market Review for H1 2017
The latest pipeline review has been done by research experts which encapsulate vital information on the Serine Protein Kinase ATM targeted therapeutics with well-updated data in H1 2017. This analysis has been added to the market intelligence repository of Market Research Hub (MRH), with the title of "Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H1 2017". The guide also covers the descriptive pharmacological action of the therapeutics on the basis of complete...
View full press release